Printer Friendly

AMYLIN PHARMACEUTICALS INC. ANNOUNCES THE ADDITION OF DR. ROBERT BUTZ AS VICE PRESIDENT, DEVELOPMENT

 AMYLIN PHARMACEUTICALS INC. ANNOUNCES THE ADDITION
 OF DR. ROBERT BUTZ AS VICE PRESIDENT, DEVELOPMENT
 SAN DIEGO, Jan. 6 /PRNewswire/ -- Amylin Pharmaceuticals Inc. today announced that Dr. Robert Butz has joined the company as vice president of development. Butz will be responsible for preclinical development, clinical research and development, clinical data management and project management, according to Dr. Tim Rink, president and chief technical officer.
 "The experience in clinical research and development that Dr. Butz is bringing to Amylin will be a tremendous asset," Rink said. "We are working toward the clinical investigation of amylin agonists and blockers, and the addition of Dr. Butz will surely expedite this process."
 With a Ph.D. in pharmacology from Duke University, Butz progressed to various positions with Burroughs Wellcome Co., including clinical research scientist. Prior to joining Amylin, Butz was vice president, clinical operations, and vice president, strategic business research at Quintiles Inc., an international contract research organization.
 San Diego-based Amylin Pharmaceuticals Inc. was co-founded in 1987 by Howard E. (Ted) Greene, chairman and chief executive officer, who was previously chief executive officer of Hybritech, and Dr. Garth Cooper, who guided the team whose efforts led to the discovery of amylin at Oxford University. Research indicates that the amylin hormone plays a key role in the normal regulation of food metabolism and storage. A deficiency of amylin appears to underlie some of the problems of type 1 (insulin dependent) diabetics who lack amylin as well as insulin. Amylin excess is believed to contribute to insulin resistant states including obesity, glucose tolerance and type 2 diabetes.
 Amylin Pharmaceuticals Inc. is a development stage pharmaceutical company working commercialize novel therapeutic products for diabetes, obesity and related health problems.
 -0- 1/6/92
 /CONTACT: Linda Seaton of The Gable Group, 619-234-1300, for Amylin Pharmaceuticals/ CO: Amylin Pharmaceuticals Inc. ST: California IN: MTC SU: PER


DM-SE -- SD004 -- 6772 01/06/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1992
Words:316
Previous Article:FINANCING OF $135 MILLION COMPLETED FOR THERMO ELECTRON'S SAN DIEGO COUNTY RECYCLING FACILITY; CONSTRUCTION SCHEDULED TO BEGIN THIS MONTH
Next Article:SILICON GRAPHICS AGAIN TOPS INDUSTRY IN WORKSTATION CUSTOMER SATISFACTION
Topics:


Related Articles
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
SENSUS ESTABLISHES SAN FRANCISCO OPERATIONS CENTER; APPOINTS PRESIDENT C.O.O.
AMYLIN PHARMACEUTICALS ANNOUNCES BOARD ADDITIONS AND MANAGEMENT CHANGE
AMYLIN PHARMACEUTICALS TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE; SUMMARY OF AMYLIN PHARMACEUTICALS' H&Q PRESENTATION
AMYLIN PHARMACEUTICALS RECRUITS SENIOR VICE PRESIDENT OF RESEARCH FROM HOECHST MARION ROUSSEL
AMYLIN PHARMACEUTICALS ELECTS NEW PRESIDENT AND CEO
Amylin Pharmaceuticals Initiates Final Pivotal Studies of Diabetes Drug Candidate
Amylin Pharmaceuticals Announces Management Promotions
Amylin Pharmaceuticals Announces Management Promotions

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters